Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients

BACKGROUND: The treatment of metastatic breast cancer (MBC) remains a great clinical challenge as drug resistance frequently develops. Alternative agents that can overcome drug resistance would offer new therapeutic options. The primary aim of this phase II study was to evaluate the efficacy and saf...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Pin, Tong, Zhongsheng, Tian, Fuguo, Wang, Yongsheng, Yang, Junlan, Li, Weilian, Di, Lijun, Liu, Wei, Tang, Li, Qiu, Rongguo, Xu, Binghe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982136/
https://www.ncbi.nlm.nih.gov/pubmed/27516093
http://dx.doi.org/10.1186/s13045-016-0297-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982136/
https://www.ncbi.nlm.nih.gov/pubmed/27516093
http://dx.doi.org/10.1186/s13045-016-0297-7

Ejemplares similares